Cerebrolysin in SAH (Subarachnoidal Haemorrhage) - Observational Study
Launched by POMERANIAN MEDICAL UNIVERSITY SZCZECIN · May 21, 2024
Trial Information
Current as of March 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age \>18 years old, diagnosis of SAH, treatment in ICU conditions
- Exclusion Criteria:
- • age \<18 years, medical history of allergy to Cerebrolysin, acute renal failure, pregnancy, multi organ trauma, death within 48 hours after admission
About Pomeranian Medical University Szczecin
Pomeranian Medical University Szczecin is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. Located in Szczecin, Poland, the university emphasizes a multidisciplinary approach to medical education and research, fostering collaboration among healthcare professionals, scientists, and industry partners. With a commitment to improving patient outcomes, Pomeranian Medical University actively engages in a variety of clinical trials that explore novel treatments and therapeutic strategies, contributing significantly to the body of medical knowledge and enhancing the quality of care within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Szczecin, , Poland
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
